DOSIsoft

Cachan, 
France
http://www.dosisoft.com
  • Booth: 423


Patient-specific dosimetry for 90Y-SIRT/177Lu Molecular RT

Founded in 2002, DOSIsoft is a leading provider of patient-specific imaging & dosimetry software in Radiation Oncology & Nuclear Medicine. Over 200 centers in 26 countries use its vendor-neutral solutions to improve patient safety & treatment quality.

PLANET® Onco: Oncology software for Molecular Imaging & Radiotherapy. It helps clinical team to optimize disease diagnosis and therapy through registration, contouring, advanced quantification and patient response from multimodal imaging. Texture analysis for diagnosis, follow-up and radiomics is also provided.

PLANET® Dose: Dosimetry software dedicated to Molecular Radiotherapy providing fully integrated 3D and hybrid 3D/2D dosimetry for 90Yttrium &177Lutetium. It allows medical team to personalize patient therapy through pre & post-implementation dosimetry, automatic structure propagation, calculation of residence time and comparison between treatment planning and validation control dose maps. Consolidation of multi-treatment stages is also available.

PLANET® Neuro: Neurology software for diagnosis of Neurological and Dementia Diseases. It is designed to improve analysis accuracy and increase medical confidence for neurodegenerative diseases especially Alzheimer, dementia with Lewy bodies, Parkinson and Epilepsy. Normality database can be created with your own SPECT/PET data.

Brands: PLANET Dose - PLANET Onco - PLANET Neuro - ThinkQA with EPIgray and EPIbeam - MU2net - ISOgray - IMAgo - SIMAgo - MorphoBOX


 Press Releases

  • Cachan| Tuesday, March 12th, 2019

    DOSIsoft, leading provider of advanced software solutions for Radiation Oncology and Nuclear Medicine, is pleased to announce it has received on March 7th, 2019, from the US Food and Drug Administration (FDA), the 510(k) clearance to market PLANET® Onco Dose software, for its Oncology and Yttrium-90 microsphere SIRT 3D Dosimetry components.

    An integrated imaging and dosimetry platform dedicated to Molecular Imaging & Molecular Radiotherapy Dosimetry

    PLANET® Onco Dose is a comprehensive software platform dedicated to medical diagnosis aid, therapy response assessment aid, contouring for radiotherapy and internal dosimetry computation, using molecular imaging modalities.

    PLANET® Onco Dose is a modular software suite composed of two main elements:

    • PLANET® Onco: The Oncology module with core System features, comprehensive reviewing of multimodal molecular image series (CT, MRI, PET, SPECT), fusion and registration, automatic and semi-automatic contouring of regions of interest, tumor segmentation, quantification, tumoral activity monitoring, therapy response assessment;
    • PLANET® Dose: The Dosimetry module including 3D personalized voxel-based internal dosimetry computation dedicated to Molecular Radiotherapy (MRT)

    PLANET® Onco provides advanced tools to display, co-register (including deformable registration), compute Standardized Uptake Value and import / export results (contours and quantification results) to / from Treatment Planning Systems and PACS devices for assessment, treatment planning and response of patients undergoing a course of oncology treatments.

    A Personalized 3D Dosimetry solution for 90Yttrium-based Selective Internal Radiation Therapy (SIRT)

    Leveraging its long-term experience, DOSIsoft has transferred its External Radiation Therapy advanced software technology to Nuclear Medicine and Molecular Radiotherapy. CE marked since March 2016, PLANET® Onco Dose is the first fully integrated imaging and personalized 3D dosimetry platform for radionuclide-based therapies.

    PLANET® Onco Dose is intended to assist the user in the diagnosis, quantification and verification of radiation doses received by tissues as a result of administering permanent Yttrium-90 (90Y) microsphere implants, as well as in therapy response follow-up.

    PLANET® Onco Dose provides tools for post-treatment absorbed dose calculation and evaluation on PET and SPECT images. The following functions are available to allow dose calculations for patients after they have received a treatment using permanent Yttrium-90 microspheres:

    • 3D liver-lung shunt assessment;
    • Voxel-based Dosimetry based on 90Y-microspheres-PET (or SPECT Bremsstrahlung) series;
    • Dose computation models: Local Deposition Method and Voxel S Value Dose Kernel Convolution approach;
    • Analysis down to any liver sub region: healthy liver, lobes, tumors, toxicity regions, …
    • Advanced and interactive dosimetry quantification (profile, dose-volume histograms, statistics, …);
    • Ability to scale to known activity;
    • Compatible with PET images acquired with another radioisotope (correction of branching ratio and decay parameters).

    The current 510(k) FDA clearance of  PLANET® Onco Dose is a great achievement and recognition of our technology and solution. We are very proud to bring this breakthrough innovation to the US medical care teams. We believe they can benefit from its full advanced functionalities in order to better and more precisely perform patient-specific 3D imaging and dosimetry for 90Yttrium SIRT cancer therapies. As a dosimetry expert company well-established in Europe, we will be bringing more innovation to the US centers with software versions supporting other radionuclide-based therapies in the near future.” comments Jean-Elie KAFROUNI, CEO of DOSIsoft Inc.

    About DOSIsoft

    Founded in 2002, DOSIsoft develops cutting-edge software solutions for Radiation Oncology and Nuclear Medicine. 16 years of innovation and R&D investments have led to world leading software solutions used successfully in over 200 hospital centers in 26 countries around the world. Spin-off between Gustave Roussy and Institut Curie, DOSIsoft constantly innovates in partnership with the major cancer institutes and research centers in the world.  www.dosisoft.com

    DOSIsoft will participate in the Annual Meeting of SNMMI from June 22nd to 25th, 2019 in Anaheim, CA, US. Come visit us at booth #423.

  • Cachan| Friday, October 12th, 2018

    DOSIsoft SA, leading provider of advanced software solutions for Radiation Oncology and Nuclear Medicine, launches a new version of PLANET® Dose – its multi-radionuclide dosimetry platform dedicated to Molecular Radiotherapy (MRT). In addition to improvements for 90Yttrium-based therapies, the new version includes the full support of 177Lutetium-based therapies. These additional developments have been performed in collaboration with the Cancer Research Center of Toulouse (CRCT)UMR 1037 Inserm / Toulouse III – Paul Sabatier University and the Institut Jules Bordet in Brussels. PLANET® Dose is the first CE marked platform on the market supporting 3D personalized dosimetry for 90Yttrium and 177Lutetium therapies.

    PLANET® Dose V3.1.1: multi-radionuclide 3D voxel-based dosimetry platform

    Complete, versatile, high performance and vendor-neutral treatment planning software solution, PLANET® Dose offers a multi-radionuclide platform supporting 90Yttrium/SIRT therapies and 177Lutetium-based radionuclide therapies. This new version enhances the previous release with specific functionalities for systemic therapies, in particular related to the pharmacokinetic modelling required for such treatments. The advanced features include: multi-time point quantification, elastic image registration, automatic deformable propagation of Volume-Of-Interest across times, residence time calculation, dose computation, consolidation of multi-treatment stages as well as advanced dose distribution analysis.

    Personalized 3D dosimetry for Lutetium-based therapies

    177Lutetium-based therapies are emerging and promising forms of Peptide Receptor Radionuclide therapies (PRRT), targeting tumors with radiolabeled molecules that bind to specific receptors expressed by the tumors. Main indications of 177Lutetium-based therapies are neuroendocrine tumors (NETs).
    Compared to 90Yttrium/SIRT therapies, 177Lutetium-based therapies belong to the family of systemic therapies, for which the modelling of the pharmacokinetics of administered radiopharmaceutic is key to compute an accurate 177Lutetium absorbed dose deposition in different parts of the body, organs at risk (e.g. kidneys) and tumor sites.
    Today, 177Lutetium-based therapies are mainly performed with standard protocols based on fixed activities and intervals between treatment cycles. Like other types of ionizing radiation therapies (External Beam Radiation Therapy huge progresses over the last ten years have demonstrated this) the personalized dose computation, with the double objective to (1) increase the absorbed dose to the tumor, and (2) maintain acceptable dose levels at organs at risk / healthy tissues, has the potential to significantly improve the therapeutic efficiency while mastering the patient safety and treatment tolerance. An individualized dosimetry-based approach will enable the delivery of higher radioactive activities at tumor sites while preserving in particular renal functions and other healthy organs.  

    PLANET® Dose meets the new European regulatory requirements (2013/59 Euratom)

    The need of doing verification of the absorbed dose delivered to individual patient and the importance of performing personalized, dosimetry-based treatment planning in the domain of Molecular Radiotherapy, has been underlined by the new European council directive (2013/59 Euratom). This represents a great challenge for radionuclide treatments, while they are given more systemically and use different radiotherapeutics available which continue to expand significantly. The new version of PLANET® Dose perfectly meets the current European regulatory requirements to provide a full personalized 3D dosimetry with a patient-oriented approach.

    We are very proud of the new version of PLANET® Dose achieved in collaboration with the CRCT – UMR 1037 Inserm / Toulouse III – Paul Sabatier University and the Institut Jules Bordet. This validation confirms the capability of PLANET® Dose to work with different radionuclides: 90Y-microspheres and 177Lutetium. We are convinced that PLANET® Dose, as the first integrated imaging and dosimetry platform for clinical routine, will help centers in the planning, in vivo control and full traceability of such treatments. It will bring the flexibility for centers to include in the future other potential radionuclides to fight specific cancer cases.”  claims Sébastien Vauclin, PLANET Product Manager at DOSIsoft SA.

    About DOSIsoft

    Founded in 2002, DOSIsoft develops cutting-edge software solutions for Radiation Oncology and Nuclear Medicine. 15 years of innovation and R&D investments have led to world leading software solutions used successfully in over 170 hospital centers in 18 countries around the world. Spin-off of Gustave Roussy and Institut Curie, DOSIsoft constantly innovates in partnership with the major cancer institutes and research centers in the world. www.dosisoft.com


 Products

  • PLANET® Onco
    Oncology software dedicated to Molecular Imaging & Radiotherapy for multimodality contouring, quantification, follow-up of therapy response & texture analysis...

  • Oncology software for Molecular Imaging & Radiotherapy. It helps clinical team to optimize disease diagnosis and therapy through registration, contouring, advanced quantification and patient response from multimodal imaging. Texture analysis for diagnosis, follow-up and radiomics is also provided.
  • PLANET® Dose
    Dosimetry software dedicated to Molecular Radiotherapy providing fully integrated 3D and hybrid 3D/2D dosimetry for 90Yttrium &177Lutetium....

  • It allows medical team to personalize patient therapy through pre & post-implementation dosimetry, automatic structure propagation, calculation of residence time and comparison between treatment planning and validation control dose maps. Consolidation of multi-treatment stages is also available.

  • PLANET® Neuro
    Neurology software for neurodegenerative diseases diagnosis (Alzheimer, dementia with Lewy bodies, Parkinson & Epilepsy)...

  • Neurology software for diagnosis of Neurological and Dementia Diseases. It is designed to improve analysis accuracy and increase medical confidence for neurodegenerative diseases especially Alzheimer, dementia with Lewy bodies, Parkinson and Epilepsy. Normality database can be created with your own SPECT/PET data.

For Technical Support with this webpage, please contact support.